Infectious and inflammatory diseases remain major contributors to morbidity and mortality worldwide. Several immune-mediated diseases in mice mimic disease pathogenesis in humans thereby making mice useful in basic research as well as translational research to evaluate impact of mutations in vivo.
The mouse is a valuable pre-clinical model, however the usefulness of the mouse as a model for disease depends on rigorous experimental design, execution, data analysis and statistics. Members of the Infection & Inflammation Core have over 20 years of experience developing and specializing in the use of infectious, autoimmune and inflammatory disease mouse models relevant to human disease.
We provide expertise, state-of-the-art infrastructure and services to enable dissection of genetics and complex biological and immunological pathways underlying the host response to pathogens and inflammation.
Our well-established mouse models allow researchers to:
- Test and characterize human candidate genes and the impact of pathogenic mutations on physiological and immune function in mice
Human IRF8 variants were associated with severe immunodeficiency and early disseminated infection by BCG vaccines in infants. Further studies in mice carrying the IRF8 variants allowed for better understanding of the role of IRF8 in transcription, monocyte and dendritic cell development, and antimycobacterial immunity. Hambleton et al., NEJM (2011)
- Investigate potential pleiotropic effects of specific genetic risk loci
A loss-of-function mutation in Usp15 was identified that protected mice from experimental cerebral malaria induced by Plasmodium berghei infection. Interestingly, the mutation in Usp15 was further shown to protect from neuroinflammation and Experimental Autoimmune Encephalomyelitis as a model of multiple sclerosis. These findings reveal that there is significant overlap between pathways regulating host defense response and inflammation. Torre et al., Nature Immunology (2017)
- Use mouse models of human infectious and inflammatory diseases to identify and test novel drug therapies
Cysteamine treatment was shown to improve anti-plasmodial activity towards blood-stage and cerebral malaria when administered in combination with artermisinin in mice. Clinical treatment with Cysteamine could improve outcomes and decrease mortality in cerebral malaria patients, as well as prevent or delay onset of resistance to artemisinins. Moradin et al., Malaria Journal (2016)
We provide fee-for-service and assist clients with:
- Study design
- Recommendations and troubleshooting
- Study execution
- Data acquisition, analysis and statistics